COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment

• Published in: Clinical cancer research 2018-07, Vol.24 (13), p.3204-3216
• Main Authors: Dong, Xiao-Feng, Liu, Tian-Qi, Zhi, Xu-Ting, Zou, Jie, Zhong, Jing-Tao, Li, Tao, Mo, Xiang-Lan, Zhou, Wei, Guo, Wen-Wen, Liu, Xia, Chen, Yuan-Yuan, Li, Meng-Yang, Zhong, Xiao-Gang, Han, Ya-Min, Wang, Zhong-Hao, Dong, Zhao-Ru
• Format: Article
• Language: English
• Subjects: Activation; Anticancer properties; Antitumor activity; Cell migration; COX-2 inhibitors; Cyclin D1; Cyclooxygenase-2; Epidermal growth factor receptors; Experimental design; Hepatocellular carcinoma; Hypoxia; Hypoxia-inducible factors; In vivo methods and tests; Inhibitors; Liver cancer; MAP kinase; Neoplasia; Nuclear transport; Prostaglandin E2; Proteins; Regulatory mechanisms (biology); Sensitivity; Translocation; Vascular endothelial growth factor; VHL protein
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-17-2725

Hypoxia-inducible factor-2α (HIF2α) is regarded as a preferential target for individualized hepatocellular carcinoma (HCC) treatment and sorafenib resistance. Our study aimed to identify the regulatory mechanisms of HIF2α activity under hypoxic conditions. We sought to determine whether the COX-2/PGE2 axis is involved in the regulatory mechanisms of HIF2α activity and of sorafenib resistance in hypoxic HCC cells. The cell viability, migration, and invasion abilities were measured to analyze the effects of HIF2α on hypoxic HCC cells. Both and HCC models were used to determine whether the COX-2/PGE2 axis is a driver of HIF2α level and activity, which then reduces the sensitivity of sorafenib treatment in hypoxic HCC cells. Under hypoxic conditions, the COX-2/PGE2 axis effectively stabilized HIF2α and increased its level and activity via decreasing von Hippel-Lindau protein (p-VHL) level, and also enhanced HIF2α activity by promoting HIF2α nuclear translocation via MAPK pathway. The activation of HIF2α then led to the enhanced activation of VEGF, cyclin D1, and TGFα/EGFR pathway to mediate HCC development and reduce the sensitivity of sorafenib. More importantly, COX-2-specific inhibitors synergistically enhanced the antitumor activity of sorafenib treatment. Our data obtained demonstrate that the COX/PGE2 axis acts as a regulator of HIF2α expression and activity to promote HCC development and reduce sorafenib sensitivity by constitutively activating the TGFα/EGFR pathway. This study highlights the potential of COX-2-specific inhibitors for HCC treatment and particularly for enhancing the response to sorafenib treatment. .